EASL’s Clinical Practice Guidelines assist physicians, healthcare providers, patients and other interested parties in the clinical decision-making process. The EASL Guidelines present a range of state-of-the-art approaches for the diagnosis and treatment of liver diseases.
The term acute liver failure (ALF) is frequently applied as a generic expression to describe patients presenting with or developing an acute episode of liver dysfunction. In the context of hepatological practice, however, ALF refers to a highly specific and rare syndrome. This means an acute abnormality of liver blood tests in an individual without underlying chronic liver disease. The disease process is associated with development of a coagulopathy of liver aetiology, and clinically apparent altered level of consciousness due to hepatic encephalopathy. Several important measures are immediately necessary when the patient presents for medical attention. These, as well as additional clinical procedures will be the subject of the Acute Liver Failure Guidelines.Read More
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care.Read More
The Clinical Practice Guidelines propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference. The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities.Read More
The first EASL Clinical Practice Guideline on treatment of hepatitis C was published in 1999. Since then, more than 30 EASL Guidelines on various liver diseases have been published. The EASL CPGs are extremely popular in Europe and beyond. Most importantly, they are a global reference for the current state-of-the-art on diagnosis and management of liver diseases. As consequence, the EASL Guideline have been widely distributed. And not only by open access publication in the Journal of Hepatology but also on the EASL website. Or through EASL smartphone apps (iLiver and the HCV Advisor), translations into other languages (e.g. Russian and Chinese). Finally, for some EASL CPGs, dissemination of knowledge into derivatives of the guidelines (e.g. patient versions).
The Success of the EASL Clinical Practice Guidelines
One possible reason for the success our guidelines is the streamlined process. This has allowed for a fast response and timely publication of clinical recommendations when there are new developments in a field. This was especially relevant for chronic HCV infection. The rapid development of treatment regimens has prompted the EASL Governing Board to commission regular updates of ‘‘HCV treatment recommendations”on an almost yearly basis since 2014. In 2019 EASL launched The first guideline for hepatitis B. Updated versions for the EASL guideline for Hepatitis B followed in 2012 and 2017.
This responsive process of CPG development in almost all areas of hepatology has only been made possible by the commitment of a small team of 5–8 world-leading experts (the ‘‘CPG panel”) and the meticulous evaluation of the CPGs by three independent experts (at least one from outside Europe), as well as the EASL Governing Board. EASL is very grateful for the continuous and outstanding support provided by these experts from our community.